NEW YORK, Sept. 22, 2017 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab”) announces the closing of its U.S. initial public offering of 9,583,333 American depositary shares (“ADSs”) at a price of US$18.00 per ADS, which includes the 1,250,000 shares sold upon full exercise of the underwriters’ option to purchase additional ADSs (the “IPO”), raising gross proceeds of approximately US$172.5 million. The ADSs have been approved for listing on the Nasdaq Global Market and began trading on September 20, 2017 under the ticker symbol “ZLAB.”
J.P. Morgan, Citigroup and Leerink Partners acted as joint book-running managers for the IPO.
In connection with the IPO, a registration statement on Form F-1 has been filed with, and declared effective by, the U.S. Securities and Exchange Commission (the “SEC”). Copies of the registration statement related to this offering can be accessed through the SEC’s website at www.sec.gov.
This offering was made only by means of a prospectus. A final prospectus may be obtained from: (i) J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: 1-866-803-9204 or email: firstname.lastname@example.org, (ii) Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or telephone: 1-800-831-9146 or (iii) Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, telephone: 1-800-808-7525 ex. 6132 or email: email@example.com.
This press release does not constitute an offer to sell or the solicitation of an offer to buy ADSs or any other securities, nor shall there be any sale of ADSs in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Zai Lab
Zai Lab (NASDAQ: ZLAB) is a Shanghai-based innovative biopharmaceutical company focused on bringing transformative medicines for cancer, autoimmune and infectious diseases to patients in China and around the world. The company’s experienced team has secured partnerships with leading global biopharma companies, generating a broad pipeline of innovative drug candidates targeting the fast growing segments of China’s pharmaceutical market and global unmet medical needs. Zai Lab’s vision is to become a fully integrated biopharmaceutical company, discovering, developing, manufacturing and commercializing its partner’s and its own products in order to impact human health worldwide.
Zai Lab Limited